Return to top of page

EMA Perspectives/Clinical Trials and Frailty

Published May 19, 2017

The AIM Coalition held a webinar on frailty with featured speaker Francesca Cerreta, senior scientific officer, ‎European Medicines Agency (EMA). In December of 2015, the EMA released a draft working paper titled “Points to consider on frailty: Evaluation instruments for baseline characteristics of clinical trial populations.” Among other considerations, this working paper includes the short physical performance battery (SPPB) and gait speed as measures of possible use in identifying vulnerable populations at risk of adverse outcomes. This webinar featured an overview of the working paper as well as the EMA geriatric strategy.

Learn more at